CT-P43: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761338's history or Celltrion's company page.
On Sep 30, 2024, FDA declined to approve CT-P43 (BLA 761338) from Celltrion Inc. in its present form, citing product quality microbiology, product quality. The application was later approved.
- Letter date: Sep 30, 2024
- Application: BLA 761338
- Since then: Approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDA(1) The bacterial retention study is inadequate for the CT-P43 drug product, 130 mg/26 mL (5 mg/mL) single-dose vial for IV Repeat the bacterial retention study of the (2) The container closure integrity test (CCIT) dye ingress method used for stability testin...… openFDA did not return the full text just now. Open it in the letter search.
Celltrion's Other Letters
Newest first- BLA 761377Mar 26, 2025 · BLA 761377 · not approved
- BLA 761377Jun 27, 2024 · BLA 761377 · not approved
- CT-P6Mar 30, 2018 · BLA 761091 · later approved
- CT-P10Feb 28, 2018 · BLA 761088 · later approved
Record
- Company
- Celltrion Inc.
- Application
- BLA 761338
- Status in openFDA
- Approved
- Review division
- Division of Dermatology and Dentistry
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters